Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

January 30, 2014

Primary Completion Date

March 20, 2018

Study Completion Date

June 30, 2026

Conditions
Breast Cancer
Interventions
PROCEDURE

Positron emission tomography (PET)

PET will be performed at baseline and on day 15

DRUG

Trastuzumab

8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV

DRUG

Pertuzumab

840 mg as a loading dose, then 420 mg every 3 weeks, IV

Trial Locations (10)

20016

Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital, Washington D.C.

27599

Lineberger Comprehensive Cancer Center, Chapel Hill

35294

University of Alabama Comprehensive Cancer Center, Birmingham

37232

Vanderbilt University, Nashville

46202

Indiana University Simon Cancer Center, Indianapolis

55905

Mayo Clinic, Rochester

77030

Baylor College of Medicine, Houston

The University of Texas MD Anderson Cancer Center, Houston

98109

Fred Hutchinson Cancer Research Center - University of Washington, Seattle

21287-0013

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Translational Breast Cancer Research Consortium

OTHER

collaborator

Genentech, Inc.

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER